Fig 1: Schematic outlining the effect of cisplatin on cell cycle arrest, DNA damage and apoptosis across the spectrum of TP53 mutation states, and the influence of P70S6K expression levels or inhibition upon these processes.
Fig 2: Response to dactolisib is dependent upon TP53 mutation status.(A) Western blotting on lysates from NCI-H358 and NCI-H1299 cells following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated. (B) Quantification of effects of dactolisib upon cisplatin induced p63 and p21 expression (n = 3, mean ± SD). (C) Western blotting on lysates from NCI-H358 cells, treated with P70S6K or control siRNA, as indicated, prior to and following a cisplatin pulse (n = 3, mean ± SD). (D) Apoptosis measured by propidium iodide staining for the sub-G1 population performed 72 hr following a cisplatin pulse with the addition of dactolisib (1 µM) as indicated (n = 3, mean ± SD). (E) Western blotting on lysates from A549 and NCI-H1573 cells, 48 hr following a cisplatin pulse, with the addition of dactolisib (1 µM), as indicated (n = 3, mean ± SD). (F) Western blotting across a second panel of lung adenocarcinoma cell lines. (G) Correlation between P70S6K phosphorylation and apoptosis, as measured by propidium iodide staining for the sub-G1 population, performed 72 hr following a cisplatin pulse (n = 3, mean ± SD). For all panels the statistical significance was determined by one-way ANOVA (***p<0.001, **p<0.01, *p<0.05).
Fig 3: P70S6K in lung adenocarcinoma.(A) The frequency of somatic mutations and mRNA over-expression for the RPS6KB1, RPS6KB2 and TP53 genes in a publically available cohort of lung adenocarcinoma patients (cBioPortal). (B) The association between RPS6KB1 and RPS6KB2 mRNA expression and overall patient survival in a publically available patient cohort (KM Plotter). Statistical significance was determined by log rank test. (C) Representative images of P70S6K immuno-histochemistry staining from a cohort of 52 lung adenocarcinoma patients (Scale bar = 100 µM). (D) Survival analysis based upon P70S6K staining in this cohort. Statistical significance was determined by log rank test. (E) The association between tumour P70S6K staining intensity (H-Score) and patients that underwent a partial response (PR), or presented with stable disease (SD) or progressive disease (PD). Statistical significance was determined by one-way ANOVA, (F) The association between tumour P70S6K staining intensity and tumour stage. Statistical significance was determined by one-way ANOVA. (G) P70S6K staining in eight matched patient samples from diagnosis and relapse (n = 8). Statistical significance was determined by t-test (*p<0.05).
Supplier Page from Cell Signaling Technology for SignalSilence ® p53 siRNA II